Cellular abnormalities of blood vessels as targets in cancer
- PMID: 15661540
- DOI: 10.1016/j.gde.2004.12.005
Cellular abnormalities of blood vessels as targets in cancer
Abstract
Tumor blood vessels have multiple structural and functional abnormalities. They are unusually dynamic, and naturally undergo sprouting, proliferation, remodeling or regression. The vessels are irregularly shaped, tortuous, and lack the normal hierarchical arrangement of arterioles, capillaries and venules. Endothelial cells in tumors have abnormalities in gene expression, require growth factors for survival and have defective barrier function to plasma proteins. Pericytes on tumor vessels are also abnormal. Aberrant endothelial cells and pericytes generate defective basement membrane. Angiogenesis inhibitors can stop the growth of tumor vessels, prune existing vessels and normalize surviving vessels. Loss of endothelial cells is not necessarily accompanied by simultaneous loss of pericytes and surrounding basement membrane, which together can then provide a scaffold for regrowth of tumor vessels. Rapid vascular regrowth reflects the ongoing drive for angiogenesis and bizarre microenvironment in tumors that promote vascular abnormalities and thereby create therapeutic targets.
Similar articles
-
Pericytes and vessel maturation during tumor angiogenesis and metastasis.Am J Hematol. 2010 Aug;85(8):593-8. doi: 10.1002/ajh.21745. Am J Hematol. 2010. PMID: 20540157 Review.
-
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.J Clin Invest. 2006 Oct;116(10):2610-21. doi: 10.1172/JCI24612. J Clin Invest. 2006. PMID: 17016557 Free PMC article.
-
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.Am J Pathol. 2004 Jul;165(1):35-52. doi: 10.1016/S0002-9440(10)63273-7. Am J Pathol. 2004. PMID: 15215160 Free PMC article.
-
Antiangiogenic therapy: creating a unique "window" of opportunity.Cancer Cell. 2004 Dec;6(6):529-31. doi: 10.1016/j.ccr.2004.12.003. Cancer Cell. 2004. PMID: 15607955
-
The role of the microenvironment and intercellular cross-talk in tumor angiogenesis.Semin Cancer Biol. 2002 Apr;12(2):105-12. doi: 10.1006/scbi.2001.0418. Semin Cancer Biol. 2002. PMID: 12027582 Review.
Cited by
-
Pericytes on the tumor vasculature: jekyll or hyde?Cancer Microenviron. 2013 Apr;6(1):1-17. doi: 10.1007/s12307-012-0102-2. Epub 2012 Mar 31. Cancer Microenviron. 2013. PMID: 22467426 Free PMC article.
-
Importance of investigating high-risk human papillomavirus in lymph node metastasis of esophageal adenocarcinoma.World J Gastroenterol. 2020 Jun 7;26(21):2729-2739. doi: 10.3748/wjg.v26.i21.2729. World J Gastroenterol. 2020. PMID: 32550750 Free PMC article. Review.
-
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Front Immunol. 2015 Mar 26;6:127. doi: 10.3389/fimmu.2015.00127. eCollection 2015. Front Immunol. 2015. PMID: 25859247 Free PMC article. Review.
-
Nanovector delivery of siRNA for cancer therapy.Cancer Gene Ther. 2012 Jun;19(6):367-73. doi: 10.1038/cgt.2012.22. Epub 2012 May 4. Cancer Gene Ther. 2012. PMID: 22555511 Free PMC article. Review.
-
Microglia-Derived Olfactomedin-like 3 Is a Potent Angiogenic Factor in Primary Mouse Brain Endothelial Cells: A Novel Target for Glioblastoma.Int J Mol Sci. 2022 Nov 23;23(23):14613. doi: 10.3390/ijms232314613. Int J Mol Sci. 2022. PMID: 36498941 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources